In vivo bioluminescence imaging of primary tumors and tumor metastasis

Slides:

Advertisements

Similar presentations

Fig. 2. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to immunotherapy. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to.

Advertisements

Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Fig. 5 Local gel scaffold for T cell memory response.

Bioluminescence imaging facilitates detection of tumor growth and metastasis in mouse orthotopic xenograft model. Bioluminescence imaging facilitates detection.

Midkine and Melanoma Metastasis: A Malevolent Mix

Pharmacologic inhibitors of PI3Kγ suppress PDAC growth and metastasis.

Sildenafil suppresses polyp formation in the AOM/DSS model of colon cancer. Sildenafil suppresses polyp formation in the AOM/DSS model of colon cancer.

Instigating, noninstigating, and responding human tumor specimens.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.

CD8 T cells play a critical role in responses of TILs due to BRAF inhibition. CD8 T cells play a critical role in responses of TILs due to BRAF inhibition.

PTENP1 serves as a ceRNA in the regulation of tumor growth in RCC

In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s

SDF-1/CXCR4 axis is involved in CD133+ tumor cell metastasis toward a lymphatic metastasis niche. SDF-1/CXCR4 axis is involved in CD133+ tumor cell metastasis.

Tumor metastasis is mediated by neutrophils.

coTCRcys-transduced T cells control tumor growth in vivo.

Stereotactic radiotherapy increases Tregs in tumors.

Effects of DPM treatment on tumor volume, tumor mass, and pulmonary metastasis at experimental end point. Effects of DPM treatment on tumor volume, tumor.

IL6 mRNA is not detected in metastatic prostate cancer cells.

EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. A,

Survival and tumor burden of mice bearing peritoneally disseminated gastric cancer. Survival and tumor burden of mice bearing peritoneally disseminated.

Accelerated metastasis spread in tumor-bearing mice treated with paclitaxel and anakinra. Accelerated metastasis spread in tumor-bearing mice treated with.

AXL is not expressed in human prostate tumors.

In vivo thrombosis of tumor vasculature.

Primary B16F10 tumor inhibits experimental metastasis formation in the lung. Primary B16F10 tumor inhibits experimental metastasis formation in the lung.

Matriptase-2 inhibited breast tumor development in vivo.

The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.

Electron microscopy. Electron microscopy. A, 8 h after irradiation. An endothelial cell is seen protruding into the lumen of the vessel. Arrow head, a.

MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting Sox2. MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting.

Experimental metastasis inhibition by primary tumors is mediated by NK cells and IFNγ. Experimental metastasis inhibition by primary tumors is mediated.

The antitumor and antimetastatic properties of PF in the MX1 orthotopic model. The antitumor and antimetastatic properties of PF in the.

PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.

In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. A,

ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells, and NK cells. ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells,

In vivo efficacy of targeted EDVTM in an orthotopic neuroblastoma mouse model with high EGFR protein levels. In vivo efficacy of targeted EDVTM in an orthotopic.

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

Antitumor effects of celastrol in vitro and in vivo.

GM-CSF is required for CA-MSC–induced tumor metastasis.

Determination of MTD for romidepsin and pralatrexate and associated antitumor activity. Determination of MTD for romidepsin and pralatrexate and associated.

HMQ1611 inhibited breast tumor growth in mice.

CD44 depletion blocks tumor cell aggregation and lung metastasis in vivo. CD44 depletion blocks tumor cell aggregation and lung metastasis in vivo. A,

Ex vivo imaging of lymph nodes with tumor metastasis using a bioluminescence imaging system. Ex vivo imaging of lymph nodes with tumor metastasis using.

Whole-mount analysis of tumor induced lymphatic sprouting by confocal microscopy. Whole-mount analysis of tumor induced lymphatic sprouting by confocal.

Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex treatment. Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex.

MDSC-derived IL-6 enhances tumor progression through the inhibition of tumor-specific TH1 development and of their helper activity for CD8+ T cells. MDSC-derived.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Model of minimal residual disease.

CDV potentiates the antitumor effect of ionizing radiation in mice intracerebrally implanted with human glioblastoma cells. CDV potentiates the antitumor.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

Myc succeeds Akt activation and is required for growth of metastatic prostate cancer. Myc succeeds Akt activation and is required for growth of metastatic.

SPARC is required for spontaneous metastasis

A, VEGFR2 staining in the tumor rim and center.

BMX inhibition suppresses the growth of CRPC cells in vitro and in vivo. BMX inhibition suppresses the growth of CRPC cells in vitro and in vivo. A, CWR22RV1.

TAE-684 effectively inhibits the growth of H3122 in vivo.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

PDL192 and inhibit the growth of xenograft tumors.

Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC.

Inhibition of spontaneous pulmonary metastasis and prolonged survival after removal of primary tumor and intratracheal delivery of rAAV2/5-VAS. Inhibition.

Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor cells after weekly CAR+ T-cell treatment for 4 wks. Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor.

W. chinensis extract attenuates tumor growth of 103E (a subline of CWR22Rv1) engrafted in the prostate of nude mice. W. chinensis extract attenuates tumor.

Transgenic mice with constitutively active NIK show increased tumor growth in bone. Transgenic mice with constitutively active NIK show increased tumor.

BV6 increases bone metastasis.

Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.

Presentation transcript:

In vivo bioluminescence imaging of primary tumors and tumor metastasis. In vivo bioluminescence imaging of primary tumors and tumor metastasis. Representative images from the mice before (A and D) or after the removal of primary tumors at week 3 (B, C, E, and F). A and B, mice treated with AdVEGFR-3-Ig 1 day after tumor implantation (day 2). C, mice treated with AdVEGFR-3-Ig on day 25 showed metastasis in the axillary lymph nodes. D-F, images of tumor bearing mice receiving AdLacZ viruses. Arrows, tumor metastasis in the lymph nodes (C-F); arrowheads, metastatic tumor cells in the draining lymphatic vessel (E). Dotted circles, primary tumor positions. G, images of axillary lymph nodes from tumor-bearing mice treated with AdVEGFR-3-Ig (top row) or AdLacZ (bottom row). H, plotting of lymph node weight from the mice with lymph node metastasis treated with AdVEGFR-3-Ig (R3-Ig) or AdLacZ (LacZ) starting on day 25. Note that blocking VEGFR-3 signaling did not suppress the growth of metastatic tumor in the lymph nodes (R3-Ig: 1.0 ± 0.93 g, n = 8; LacZ: 1.12 ± 1.27 g, n = 5; P = 0.8471). Yulong He et al. Cancer Res 2005;65:4739-4746 ©2005 by American Association for Cancer Research